Real Life Clinical Effectiveness of Razumab® (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration: A Subgroup Analysis of Pooled Retrospective RE-ENACT Study

Wet age-related macular degeneration (wet AMD), a leading cause of vision loss globally, is a late-onset, multifactorial retinal degenerative disease. The characteristic features of wet AMD are neovascularization originating from the choroidal vasculature and spreading to the subretinal pigment epithelium or subretinal space, and increased intraretinal (IRF) or subretinal fluid (SRF) [1-4]. The increased choroidal neovascularization (CNV), IRF and SRF are associated with over expression of vascular endothelial growth factor (VEGF)-A, which promotes neovascularization and leakage leading to wet AMD [5, 6].